| Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. | |
| | |
MedLine Citation:
|
PMID: 20548817 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Platelets are crucial in the pathogenesis of acute coronary syndrome. Treatment for acute coronary syndrome usually involves antiplatelet, anticoagulant, and antithrombotic therapy, and the performance of percutaneous coronary intervention. All of the medications are associated with bleeding sequelae and are typically withheld from patients who have thrombocytopenia. The safety of antiplatelet therapy and percutaneous coronary intervention in patients who have acute coronary syndrome and thrombocytopenia is unknown, and there are no guidelines or randomized studies to suggest a treatment approach in such patients. Acute coronary syndrome is uncommon in patients who have thrombocytopenia; however, it occurs in up to 39% of patients who have both thrombocytopenia and cancer. Herein, we present the cases of 5 patients with acute coronary syndrome, thrombocytopenia, and cancer who underwent percutaneous coronary intervention with stenting. Before intervention, their platelet counts ranged from 17 to 72 x 10(9)/L. One patient underwent preprocedural platelet transfusion. All were given aspirin, alone or with clopidogrel. One patient experienced melena (of colonic origin). No other patient experienced bleeding sequelae. Aside from the occasional use of antiplatelet and thrombolytic agents in patients with thrombocytopenia, no therapeutic recommendation can be made until data are available on a larger patient population. Until then, treatment should conform to specific clinical circumstances. Approaches to the treatment of acute coronary syndrome in patients with thrombocytopenia might be better directed toward the evaluation of platelet function rather than toward absolute platelet count, and the risk-benefit equation of invasive procedures and antithrombotic therapies may need to incorporate this information. |
| | |
Authors:
|
Syed Wamique Yusuf; Cezar Iliescu; Jaya D Bathina; Iyad N Daher; Jean-Bernard Durand |
Related Documents
:
|
20530057 - Association of the c677t mthfr polymorphism with homocysteine, ox-ldl levels, and thiol... 21373727 - Adefovir-induced stevens-johnson syndrome and toxic epidermal necrolysis overlap syndrome. 21158507 - An approach to deep brain stimulation for severe treatment-refractory tourette syndrome... 18669427 - Smoke-free legislation and hospitalizations for acute coronary syndrome. 19966877 - Intravenous immunoglobulin therapy for neurological disorders. 2634137 - A case of incomplete digeorge syndrome associated with partial monosomy 22q11.1 due to ... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital Volume: 37 ISSN: 1526-6702 ISO Abbreviation: Tex Heart Inst J Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-06-15 Completed Date: 2010-09-27 Revised Date: 2010-09-30 |
Medline Journal Info:
|
Nlm Unique ID: 8214622 Medline TA: Tex Heart Inst J Country: United States |
Other Details:
|
Languages: eng Pagination: 336-40 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. syusuf@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
blood,
complications,
therapy* Aged Aged, 80 and over Angioplasty, Transluminal, Percutaneous Coronary* / instrumentation Aspirin / adverse effects, therapeutic use* Drug Therapy, Combination Female Hemorrhage / chemically induced Humans Male Melena / chemically induced Middle Aged Neoplasms / blood, complications* Patient Selection Platelet Aggregation Inhibitors / adverse effects, therapeutic use* Platelet Count Platelet Transfusion Risk Assessment Stents Thrombocytopenia / blood, complications* Ticlopidine / adverse effects, analogs & derivatives*, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The true teacher.
Next Document: Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.